case_images: PMC4821155_01
case_images: CT scan pretreatment and at 4 weeks demonstrating enlargement of a supraclavicular node (red arrow).
case_images: cro-0009-0164-g02.jpg
case_images: PMC4821155_01_cro-0009-0164-g02.jpg
case_images: F2
case_images: The 'growth' on CT scan (fig. 2) was significant enough (3.05-3.33 cm) to discontinue RRx-001.
case_images: Graph plotting relative cellularity, necrosis and T cell infiltrate per 40x high-power field (HPF) pretreatment vs. 6 and 12 weeks posttreatment using a customized scoring scale from 0 to 3. Scoring was carried out as follows: cellularity by Ki-67 index: 1 = <2%, 2 = 2-20%, 3 = >20%; necrosis: 1 = punctuate/focal, 2 = geographic, 3 = widespread. T cell infiltrate: scoring by number of CD3+ T-cells per 40x HPF. LN = Lymph node.
case_images: cro-0009-0164-g03.jpg
case_images: PMC4821155_01_cro-0009-0164-g03.jpg
case_images: F3
case_images: T cell infiltrate as demonstrated on the graphs below (fig. 3). The percentage of histologically intact tumor and the percentage of necrotic tumor were scored per slide.
case_images: CT scan at 4 weeks and at 8 weeks demonstrating shrinkage of the supraclavicular node (red arrow), indicative of pseudoprogression.
case_images: cro-0009-0164-g04.jpg
case_images: PMC4821155_01_cro-0009-0164-g04.jpg
case_images: F4